Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Klaus Fellermann

Showing results (21-30 of 53) with videos related to

Pageof 6
Sort By:
Inflammatory Bowel Diseases|December 14, 2002
Response of refractory colitis to intravenous or oral tacrolimus (FK506)Klaus Fellermann, Zita Tanko, Klaus R Herrlinger, et al.
Inflammatory Bowel Diseases|August 5, 2004
Serum procalcitonin differentiates inflammatory bowel disease and self-limited colitisKlaus R Herrlinger, Rike Dittmann, Gunther Weitz, et al.
Inflammatory Intestinal Diseases|July 19, 2018
Cyclophosphamide Pulse Therapy in Severe Refractory Crohn's Disease: A Retrospective Multicenter Case SeriesFlorian Bär, Thomas Krause, Andreas Stallmach, et al.
Biomed Research International|November 6, 2015
Management of Food-Related Diarrhea Outbreak in the Emergency Department: Lessons Learned from the German STEC O104:H4 EpidemicFriedhelm Sayk, Niels Henrik Asselborn, Nora Eisemann, et al.
Inflammatory Bowel Diseases|January 1, 2005
Autoantibodies against the bactericidal/permeability-increasing protein from inflammatory bowel disease patients can impair the antibiotic activity of bactericidal/permeability-increasing proteinSusanne Schinke, Klaus Fellermann, Karen Herlyn, et al.
European Journal of Gastroenterology & Hepatology|April 30, 2015
Liver steatosis is a risk factor for hepatotoxicity in patients with inflammatory bowel disease under immunosuppressive treatmentTorsten Schröder, Klaus J Schmidt, Vera Olsen, et al.
Inflammatory Bowel Diseases|August 7, 2003
Inducible and constitutive beta-defensins are differentially expressed in Crohn's disease and ulcerative colitisJan Wehkamp, Juergen Harder, Michael Weichenthal, et al.
Journal of Crohn'S & Colitis|December 22, 2010
Herpes simplex virus colitis complicating ulcerative colitis: A case report and brief review on superinfectionsMarco Oliver Schunter, Thorsten Walles, Peter Fritz, et al.
European Journal of Gastroenterology & Hepatology|May 17, 2006
Heterogeneous expression of human cathelicidin hCAP18/LL-37 in inflammatory bowel diseasesJürgen Schauber, Daniel Rieger, Frank Weiler, et al.
Microbes and Infection|April 29, 2009
Antibacterial activity of human defensins on anaerobic intestinal bacterial species: a major role of HBD-3Sabine Nuding, Lutz T Zabel, Corinne Enders, et al.
Pageof 6

Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
Inflammatory Bowel Diseases|December 14, 2002
Response of refractory colitis to intravenous or oral tacrolimus (FK506)Klaus Fellermann, Zita Tanko, Klaus R Herrlinger, et al.
Inflammatory Bowel Diseases|August 5, 2004
Serum procalcitonin differentiates inflammatory bowel disease and self-limited colitisKlaus R Herrlinger, Rike Dittmann, Gunther Weitz, et al.
Inflammatory Intestinal Diseases|July 19, 2018
Cyclophosphamide Pulse Therapy in Severe Refractory Crohn's Disease: A Retrospective Multicenter Case SeriesFlorian Bär, Thomas Krause, Andreas Stallmach, et al.
Biomed Research International|November 6, 2015
Management of Food-Related Diarrhea Outbreak in the Emergency Department: Lessons Learned from the German STEC O104:H4 EpidemicFriedhelm Sayk, Niels Henrik Asselborn, Nora Eisemann, et al.
Inflammatory Bowel Diseases|January 1, 2005
Autoantibodies against the bactericidal/permeability-increasing protein from inflammatory bowel disease patients can impair the antibiotic activity of bactericidal/permeability-increasing proteinSusanne Schinke, Klaus Fellermann, Karen Herlyn, et al.
European Journal of Gastroenterology & Hepatology|April 30, 2015
Liver steatosis is a risk factor for hepatotoxicity in patients with inflammatory bowel disease under immunosuppressive treatmentTorsten Schröder, Klaus J Schmidt, Vera Olsen, et al.
Inflammatory Bowel Diseases|August 7, 2003
Inducible and constitutive beta-defensins are differentially expressed in Crohn's disease and ulcerative colitisJan Wehkamp, Juergen Harder, Michael Weichenthal, et al.
Journal of Crohn'S & Colitis|December 22, 2010
Herpes simplex virus colitis complicating ulcerative colitis: A case report and brief review on superinfectionsMarco Oliver Schunter, Thorsten Walles, Peter Fritz, et al.
European Journal of Gastroenterology & Hepatology|May 17, 2006
Heterogeneous expression of human cathelicidin hCAP18/LL-37 in inflammatory bowel diseasesJürgen Schauber, Daniel Rieger, Frank Weiler, et al.
Microbes and Infection|April 29, 2009
Antibacterial activity of human defensins on anaerobic intestinal bacterial species: a major role of HBD-3Sabine Nuding, Lutz T Zabel, Corinne Enders, et al.
Pageof 6